ADC Therapeutics (ADCT) EBIT Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted quarterly EBIT Margin of 121.07% for Q1 2026, up 251.0% year-on-year from 34.49% in Q1 2025, and up 35.78% on a QoQ basis from 188.52% in Q3 2025.
ADC Therapeutics (ADCT) EBIT Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported EBIT Margin for 6 consecutive years, with 121.07% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 31.68% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 23.02% |
| 10 | ADC Therapeutics | 175.72 Mn | -55.29 Mn | 17.38 Mn | -121.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121.07% |
| Sep 30, 2025 | -188.52% |
| Jun 30, 2025 | -234.34% |
| Mar 31, 2025 | -123.58% |
| Sep 30, 2024 | -192.61% |
| Jun 30, 2024 | -166.81% |
| Mar 31, 2024 | -186.19% |
| Sep 30, 2023 | -249.42% |
| Jun 30, 2023 | -205.62% |
| Mar 31, 2023 | -271.55% |
| Sep 30, 2022 | -4.08% |
| Jun 30, 2022 | -401.43% |
| Mar 31, 2022 | -86.81% |
| Sep 30, 2021 | -439.58% |
| Jun 30, 2021 | -1,874.52% |